In:
Oncology, S. Karger AG, Vol. 101, No. 1 ( 2023), p. 22-31
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Original FOLFIRINOX (oFFX) is more toxic than other regimens for patients with metastatic pancreatic cancer (mPC); therefore, a modified FFX (mFFX) regimen with a reduced dosage has been used in Japanese clinical practice. However, very few studies have compared these two regimens. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 This study was conducted as part of a multicenter retrospective study of 318 patients with mPC across 14 centers in Japan (NAPOLEON study). To control for potential bias and confounders, we conducted a propensity score-adjusted analysis of patient characteristics and clinical outcomes. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 oFFX and mFFX were administered to 48 and 54 patients. More patients with younger age and poorer performance status were included in the oFFX group. The overall survival (OS; median, 11.6 vs. 11.3 months; hazard ratio [HR], 0.91; 95% confidence interval [CI] , 0.60–1.40; 〈 i 〉 p 〈 /i 〉 = 0.67), progression-free survival (PFS) (median, 6.3 vs. 5.7 months; HR, 0.85; 95% CI, 0.56–1.28; 〈 i 〉 p 〈 /i 〉 = 0.44), and overall response rate (29 vs. 26%, 〈 i 〉 p 〈 /i 〉 = 0.71) were not significantly different for the oFFX and mFFX groups. Thrombopenia and liver dysfunction were significantly more frequent with oFFX than with mFFX. The median received dose intensity of CPT-11 was higher with oFFX than with mFFX (299 vs. 270 mg/m 〈 sup 〉 2 〈 /sup 〉 /week, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.01). The propensity score-adjusted analysis revealed no statistically significant differences in OS and PFS between the two groups. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 In our data, there was no significant difference in efficacy between mFFX and oFFX, and mFFX has fewer adverse events.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2023
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Bookmarklink